Thank you and welcome, everybody to our Year-End Report. Today is February 26th, 2026. And as usual, I will start with the summary. So we had a couple of key events in the fourth quarter.
First of all, the two ASH data sets. So with BI-1808, our lead candidate, targeting TNFR2, we saw very strong data in T-cell lymphoma. And we presented that at ASH 2025. And I come back to the data a little bit more in detail later. And then we had another ASH presentation about BI-1206, which is our lead candidate targeting FcγRIIB, in combination with rituximab and Calquence in non-Hodgkin's lymphoma.
And that was also presented at ASH 2025.
And also a very, very strong data set.
I should mention that BI-1808 was monotherapy. Single agent therapy.
Then we also started our Phase 2 trial evaluating BI-1206 in combination with pembrolizumab in treatment-naïve, advanced or metastatic non-small cell lung cancer and uveal melanoma. So this is really the first line setting.
And this is, as I will explain later, based on data we have seen in patients in later lines of therapy. And that data actually convinced Merck to join us in the first-line setting under a supply and collaboration agreement. And then last but not least, we also got Orphan Drug Designation from EMA for BI-1808.
Another very important milestone for the treatment of cutaneous T-cell lymphoma. CTCL. And then we had another couple of events after the end of the period.
Number one, obviously, a very promising data set in our ongoing Phase 2 study for BI-1808 with KEYTRUDA for the treatment of recurrent ovarian cancer. And we published that ahead of JP Morgan and I will also discuss that data set a little bit more in detail.
And then we had a year-end report, and maybe not everybody is aware about this, but I will highlight it, updated clinical data sets for BI-1808 and pembrolizumab in combination in ovarian cancer, as well as the BI-1206 study for the treatment of Non-Hodgkin Lymphoma.
So we have additional patients there. And I will mention it again when we discuss specifically those two data sets.
And then also, very happy that we could nominate two new board members. Of course, they still need to be confirmed and elected at the annual general meeting. Number one, Kate Hermans. Very experienced and seasoned business person in the pharma and biotech industry.
And then Scott Zinober, who was for roughly 20 years the portfolio manager at Viking. So both two very, very strong US profiles. And we're very happy to welcome them to our board. Then before I go into a little bit more in detail, just to have a quick look at our clinical pipeline, as usual, I always emphasize here. So we have multiple value drivers.
As you know, in August, we focused on the two more mature programs, BI-1808 and BI-1206, and BI-1808 is currently running in combination with pembrolizumab in recurrent ovarian cancer.
And then we have this very nice data set that is actually continuing to generate good data. And then we have planned a new combination study. So this has not been started yet.
A combination with BI-1808, pembrolizumab, and paclitaxel, based on the very interesting data that Merck published at ESMO.
And this is actually quite exciting because it could lead to a very interesting development in recurrent ovarian cancer.
Then, obviously, as you already know. Cutaneous T-cell lymphoma. Let's briefly go over the single-agent data that we presented at ASH. And then we are currently running this also in combination with pembrolizumab, although we already have very strong single agent data in cutaneous T-cell lymphoma of BI-1808, we still want to see how it looks in combination with pembrolizumab. And then BI-1206, the triplet targeting non-Hodgkin’s Lymphoma, specifically follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma. And there we also have an update. The data set is maturing further and basically confirming the trend, as we also see in the data set in ovarian cancer in combination with pembrolizumab. So that is really very, very encouraging.
As already mentioned on the previous slide.
So we kicked off first-line combination with pembrolizumab. 1206 in non-small cell lung cancer and uveal melanoma. And there we will see the first readout already during the second half of this year.
But I will come back to the milestones this year and also an outlook into 2027.
Later, at the end of the presentation, I just want to mention that we see complete and partial responses in all clinical programs, which is truly confirming that the two single agents have activity in both liquid and solid cancer, which I find very comforting.
And that's what you want to see at this stage, then going a little bit more into detail. So first, our anti-TNF receptor 2 program, BI-1808, in solid tumors, and then the same in T-cell lymphoma.
As already mentioned, we have very promising efficacy in ovarian cancer. And that is building on the single agent activity that we have seen in ovarian cancer. But obviously if you want to treat something like recurring ovarian cancer, you have to go into combination.
And since we knew preclinically already that we have strong single agent activity, but also very good synergy with pembrolizumab, it was a no brainer. And that's why we did this. And, in addition to the data that we have shown ahead of J.P. Morgan, we have one additional partial response. So, one stable disease has now turned into a partial response, and there is one additional stable disease, bringing the overall response rate to 24% and the disease control rate to 57%. So basically, the data set that we have shown ahead of J.P. Morgan is being confirmed as it matures further into the right direction.
So, again, 24% Overall Response Rate, 57% disease control, and 21 evaluable ovarian cancer patients, which I think is very encouraging and is showing the right trend.
And also, when we look on the next slide at the spider plot, you can also see how immunotherapy is working. And we have the firm belief that BI-1808 could be potentially the next KEYTRUDA.
And you see here two dotted lines. A pink one, which is basically, if you are above this, it is progressive disease. If you are below this, it is stable disease.
And then you have a yellow line.
A Partial Response is achieved if you then go below this, and you can see how immunotherapy is working.
So you have patients at stable disease and then they're there for a while. The immune system works, and then it gets pushed down into partial response.
And this is actually very interesting because, when you look at KEYTRUDA alone, it is around 80%, or in combination with our drug, it is 24%. I think this is actually a very interesting and strong data set, and of course, further maturing, then switching to cutaneous T-cell lymphoma and Peripheral T-cell Lymphoma, our T-cell lymphoma data that we presented at ASH 2025. And there we have shown 46% Objective Response Rate and 92% Disease Control Rate in 13 evaluable CTCL patients. Very strong data set. And I should also mention here, both data sets. So the one in Ovarian cancer, as well as the one in T-cell lymphoma, also have a very excellent safety profile.
So it's very, very well tolerated, which is important, especially when you think about the combination in ovarian cancer with pembrolizumab, because you are only able to do this in case you have a good safety profile, which we have.
But going back to T-cell lymphoma here on this slide. So, what is important, besides the good safety profile, is that we see immune activation early on, with depletion of regulatory T cells and the influx of CD8 positive T cells into the skin. So we have a clear skin component. And very briefly on the spider plots here, you can also see nice duration already here in this case, the black line.
This is basically below that is stable disease. And then you see the dotted line, and below it is partial response. And you can see that we already have a complete response now in Sézary Syndrome which is really continuing for more than a year. So, you can also see that duration is coming into play here, as you could see for the earlier ovarian cancer data set. So it really looks very promising. Then, switching to our other program, our anti-FcγRIIB program BI-1206 in Non-Hodgkin’s Lymphoma, as well as in solid tumors, starting with Non-Hodgkin’s Lymphoma. So this is the combination with rituximab and acalabrutinib. So it's a triplet. And this is a little bit different slide that we have shown so far. So we'll be splitting up now into follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma. We see good responses in both. Dark green is complete. Light green is partial. And, compared with the data set that we showed at the end of last year, we now have additional partial responses and one additional stable disease, maintaining the very good 80% Objective Response Rate and a Disease Control Rate of 100%, which is excellent.
And you can see activity in all three subsets.
We are focusing more on follicular lymphoma because this is also more interesting for our supply and collaboration partner AstraZeneca, because they don't have follicular lymphoma on the label of Acalabrutinib. Then again, on this spider plot, everything below the dotted line is good because that means it's either a partial response or a complete response. And then you see also quite a number of stable diseases.
And you see here also that the data matures. That means you see stable disease.
Then it goes into partial response and then eventually into complete response. And we also have very good duration here.
And we have some idea about the duration from our study that we did before.
That was just 1206 in combination with rituximab. And of course, the patient population we're focusing on consists of patients who no longer respond to anti-CD20 based therapy. And there we have now a couple of patients that actually are in complete response for several years after the end of the study.
So then on the solid cancer side for 1206, this is a data set that is from the dose escalation where we were targeting patients.
End-of-the-line patients that do not respond anymore to either anti-PD-1 or anti-PD-L1, where we also had some very interesting signals. So we had very interesting complete and partial responses. And based on that, we went back to Merck, and our partner here for the supply collaboration on combination with Keytruda, and we agreed that we should go into Phase 2, a first-line non-small cell lung cancer and melanoma with BI-1206 and pembrolizumab.
And this is now ongoing. As I said, the first readout will be during the second half of this year, which is pretty soon. Then I will hand over to Stefan.